Your browser doesn't support javascript.
loading
Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.
Pasi, K J; Collins, P W; Keeling, D M; Brown, S A; Cumming, A M; Dolan, G C; Hay, C R M; Hill, F G H; Laffan, M; Peake, I R.
Affiliation
  • Pasi KJ; Department of Haematology, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK. k.j.pasi@qmul.ac.uk
Haemophilia ; 10(3): 218-31, 2004 May.
Article in En | MEDLINE | ID: mdl-15086319
ABSTRACT
von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Von Willebrand Diseases Type of study: Guideline Limits: Humans Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2004 Document type: Article Affiliation country:
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Von Willebrand Diseases Type of study: Guideline Limits: Humans Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2004 Document type: Article Affiliation country: